Pharmacoeconomic analysis of patients with the management of arterial hypertension with the use of bisoprolol


如何引用文章

全文:

详细

The comparative pharmacoeconomic analysis of the treatment of arterial hypertension (AH) by medications bisoprolol (Bisogamma and Concor) based on study conducted by Shostak N. et al. (2008) showed that the Bisogamma administration is scientifically well-founded approach to the treatment of hypertension in middle age patients from an economic point of view. Compared with Concor, Bisogamma clinical benefits (efficiency, estimated by the number of cases achieving the target blood pressure) is accompanied by substantial economic benefits, which amounted to 22 984 rubles in the treatment of 100 patients within 60 days, including hospital and outpatient phases. Based on the these data, the transition from Concor on Bisogamma will allow further treat 2.5% of patients, that has great economic importance, given the high prevalence of hypertension in the population.

作者简介

A Kulikov

A Kulikov

参考

  1. Шостак Н.А., Рашид М.А., Аринина Е.Е. и др. Эффективность и безопасность применения Бисогаммы и Конкора для лечения артериальной гипертензии у больных среднего возраста //Фарматека. 2008. № 12. С. 91-99.
  2. Стандарты медикаментозного лечения основных заболеваний в амбулаторно-поликлинических учреждениях препаратами, включенными в перечень лекарственных средств и изделий медицинского назначения, отпускаемых по рецептам врачей бесплатно или со скидкой в городе Москве. Правительство Москвы. Департамент здравоохранения города Москвы. М., 2005. С. 6-8.
  3. www.protek.ru <http://www.protek.ru>
  4. www.medlux.ru <http://www.medlux.ru>.
  5. Московские городские стандарты стационарной медицинской помощи для взрослого населения. Комитет здравоохранения города Москвы. М., 1997. С. 128-129.
  6. Бекетов А.С. Применение анализа "затраты-эффективность" для выбора препаратов из группы аналогов // Качественная клиническая практика. 2002. № 2.
  7. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации // Российский кардиологический журнал. 2006. № 4. С. 45-50.
  8. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
  9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
  10. Kannel WB. Prevalence and implications of uncontrolled systolic hyper-tension. Drugs Aging 2003;20:277-86.
  11. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
  12. Ohira T, Shahar E, Chambless LE, et al. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities Study. Stroke 2006;37:2493-98.
  13. Kannel WB. Current status of the epidemiology of heart failure. Curr Cardiol Rep 1999;1:11-19.
  14. Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-41.
  15. Lawes CM, Vander Hoorn S, Law MR, et al. Blood pressure and the global burden of disease 2000, part II: estimates of attributable burden. J Hypertens 2006;24:423-30.
  16. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vascular health and risk management 2007;6(3):783-95.
  17. Рекомендаций экспертов ВНОК по диагностике и лечению артериальной гипертензии 2008 г. http://www.cardiosite.ru/recommendations/article.asp?id=5491
  18. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75.
  19. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151.
  20. Глезер М.Г. Отдадут ли первенство β-адреноблокаторы в лечении артериальной гипертонии? Материалы образовательного мастер-курса по артериальной гипертонии и сердечно-сосудистому риску // Консилиум (экстравыпуск). 2007. С. 11.
  21. Psaty BM <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Psaty%20BM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Lumley T <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lumley%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Furberg CD <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Furberg%20CD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA <javascript:AL_get(this,%20'jour',%20'JAMA.');> 2003;289(19):2534-44.
  22. Wiysonge CS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wiysonge%20CS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Bradley H <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bradley%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Mayosi BM <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mayosi%20BM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev <javascript:AL_get(this,%20'jour',%20'Cochrane%20Database%20Syst%20Rev.');> 2007;24(1):CD002003.
  23. Bradley HA <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bradley%20HA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Wiysonge CS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wiysonge%20CS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Volmink JA <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Volmink%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens <javascript:AL_get(this,%20'jour',%20'J%20Hypertens.');> 2006;24(11):2131-41.
  24. Wassertheil-Smoller S <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wassertheil-Smoller%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Psaty B <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Psaty%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Greenland P <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Greenland%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA <javascript:AL_get(this,%20'jour',%20'JAMA.');> 2004;292(23):2849-59.
  25. Cruickshank JM <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cruickshank%20JM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. Are we misunderstanding beta-blockers. Int J Cardiol <javascript:AL_get(this,%20'jour',%20'Int%20J%20Cardiol.');> 2007;120(1):10-27.
  26. Booth N, Jula A, Aronem P, et al. Cost-effectiveness analysis of guidelines for antihypertensive care in Finland. BMC Health Services research 2007;7:172-86.
  27. Rabbani A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rabbani%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Alexander GC <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Alexander%20GC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens <javascript:AL_get(this,%20'jour',%20'Am%20J%20Hypertens.');> 2008;21(5):509-13.
  28. Elliot W, et al. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) <javascript:AL_get(this,%20'jour',%20'J%20Clin%20Hypertens%20(Greenwich).');> 2008;10(1 Suppl. 1):20-26.
  29. Vinker S <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Vinker%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Alkalay A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Alkalay%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Hoffman RD <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hoffman%20RD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin Pharmacother <javascript:AL_get(this,%20'jour',%20'Expert%20Opin%20Pharmacother.');> 2008;9(8):1271-77.
  30. Saleh SS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Saleh%20SS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Szebenyi S <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Szebenyi%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Carter JA <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Carter%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Patterns and associated health services costs of antihypertensive drug modifications. J Clin Hypertens (Greenwich) <javascript:AL_get(this,%20'jour',%20'J%20Clin%20Hypertens%20(Greenwich).');> 2008;10(1):43-50.
  31. Laguna-Goya N <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Laguna-Goya%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Blazquez-Perez A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bl%C3%A1zquez-P%C3%A9rez%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Pozo-Hernandez C <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pozo-Hern%C3%A1ndez%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. Regulation about generics approval. Farm Hosp <javascript:AL_get(this,%20'jour',%20'Farm%20Hosp.');> 2006;30(6):379-84.
  32. Tschabitscher D <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tschabitscher%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Platzer P <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Platzer%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Baumgartel C <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Baumg%C3%A4rtel%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Generic drugs: quality, efficacy, safety and interchangeability. Wien Klin Wochenschr <javascript:AL_get(this,%20'jour',%20'Wien%20Klin%20Wochenschr.');> 2008;120(3-4):63-69.
  33. Federman AD <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Federman%20AD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Halm EA <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Halm%20EA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Siu AL <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Siu%20AL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care 2007;45(2):109-15.
  34. Kesselheim А, et al. JAMA 2008;300:2514-26.
  35. Марцевич С.Ю., Толпыгина С.Н., Шилова Е.В. и др. Препараты бисопролола в сравнительном исследовании эффективности и переносимости оригинального препарата и его дженерика у больных мягкой и умеренной артериальной гипертонией // Кардиоваскулярная терапия и профилактика. 2007. № 6. С. 16-17.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##